Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Neil Flanzraich
AddedMar 31, 2024
UpdatedMay 31, 2026
Neil Flanzraich

Neil Flanzraich

CEO, Kirax

Crunchbase

Neil Flanzraich's Career

Kirax
Kirax

Bonita Springs, FL, US

CEO· C-Suite · Management
Alzheon
Alzheon

Framingham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Neil Flanzraich's Career

Kirax
Kirax
Public$540.8k62012Bonita Springs, FL, US
CEO· C-Suite · Management

Leadership at Kirax

Joshua KazamJoshua KazamBoard Member
Peter Morgan KashPeter Morgan KashBoard Member
Edmundo MunizEdmundo MunizFounder

Similar to Kirax

Tigris PharmaceuticalsTigris PharmaceuticalsBonita Springs, FL, USCancer Treatmentsest. 2005Tigris PharmaceuticalsBonita Springs, FL, US · est. 2005

Tigris Pharmaceuticals: Innovating biopharmaceutical solutions for cancer and other medical needs.

Series C · $32.5M6
Baudax BioBaudax BioMalvern, PA, USPharmaceuticalsest. 2019Baudax BioMalvern, PA, US · est. 2019

Baudax Bio: A specialty pharma company innovating acute care solutions.

Public · $116.2M20
Karyopharm TherapeuticsKaryopharm TherapeuticsNewton, MA, USPharmaceuticalsest. 2008Karyopharm TherapeuticsNewton, MA, US · est. 2008

US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.

Public · $546.7M385
Kira PharmaceuticalsKira PharmaceuticalsCambridge, MA, USBiotechnology, Therapeuticsest. 2017Kira PharmaceuticalsCambridge, MA, US · est. 2017

Kira Pharmaceuticals: A global biotech leader, pioneering in complement disease therapies, with a robust pipeline.

Series B · $99.5M27
Alzheon
Alzheon
Seed$140M112013Framingham, MA, US
Board Member· Board

Recent news

Alphabet is increasingly launching ‘moonshot’ projects as independent companies — here’s whyTechCrunch · 2025
Astro Teller is joining us at TechCrunch Disrupt 2025 in OctoberTechCrunch · 2025

Leadership at Alzheon

Diane JorkaskyDiane JorkaskyBoard Member
Christopher Noel DunnChristopher Noel DunnBoard Member
Martin TolarMartin TolarBoard Member
Jordan HellerJordan HellerBoard Member

Similar to Alzheon

Alzeca BiosciencesAlzeca BiosciencesHouston, TX, USMedical Diagnosticsest. 2012Alzeca BiosciencesHouston, TX, US · est. 2012

Alzeca Biosciences: Pioneering targeted MRI systems for early diagnosis of neurodegenerative diseases.

Series A · $11M20
Allyx TherapeuticsAllyx TherapeuticsNew Haven, CT, USTherapeuticsest. 2018Allyx TherapeuticsNew Haven, CT, US · est. 2018

Allyx Therapeutics: Clinical-stage biotech firm developing therapies to combat Alzheimer's disease.

Seed · $10.1M4
AztherapiesAztherapiesBoston, MA, USTherapiesest. 2011AztherapiesBoston, MA, US · est. 2011

AZTherapies: A Boston-based life science firm innovating therapies for neurodegenerative diseases.

Series B · $99.8M38
Alkeus PharmaceuticalsAlkeus PharmaceuticalsBoston, MA, USPharmaceuticals, Therapeuticsest. 2011Alkeus PharmaceuticalsBoston, MA, US · est. 2011

Alkeus Pharmaceuticals: A Boston-based startup innovating treatments for serious eye conditions.

Series B · $150.1M15

Neil Flanzraich's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Neil Flanzraich

Amir KhanAmir KhanBoard Member · AlkiraTim PeluraTim PeluraCEO · OptiKiraRich EarleyRich EarleyBoard Member · IrishAngelsPaul SauronPaul SauronFounder · AxirFrank AdellFrank AdellCEO · Neuro-KinesisTroy PolanTroy PolanCEO · Excelerarx